Clinical Trial Update: Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of 1% tenofovir vaginal gel completed to characterize systemic and vaginal tissue exposure for HIV prevention.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Tenofovir vaginal gel (1%) (tenofovir)

Snippet

Sponsor: CONRAD | Conditions: HIV Infections | Phase 1 | Status: COMPLETED